Novartis files patent infringement suit against AstraZeneca, Biogen Idec and Alexion

Novartis filed a lawsuit in a US federal court against AstraZeneca's MedImmune subsidiary, Biogen Idec and Alexion Pharmaceuticals alleging that several of the drugs that they make infringe a patent for diagnostic gene sequences. Specifically, the company said that AstraZeneca's Synagis, Biogen Idec's Tysabri and Alexion's Soliris infringe a patent that it acquired when it purchased Chiron in 2006.

To read more Top Story articles, click here.

Reference Articles